Rheumatoid Arthritis Trial, Recruiting NCT05413759 Sponsor: Hospices Civils de Lyon Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT05413759
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with rheumatoid arthritis (RA)
  • You are 18 years old or older (male or female)
  • You are either staying in hospital or attending an outpatient appointment in a rheumatology department, and you return home after your visit
  • You are currently taking or starting certain RA medications — specifically at least one of the following: methotrexate, a JAK inhibitor tablet, or an injectable biologic medication
  • You are able to manage and take your own medications independently at home
  • You can understand and speak French
  • You are covered by the French national health insurance system or an equivalent scheme
  • You have agreed to take part by giving your free, informed, and signed consent

Who may not be able to join:

  • Your usual pharmacy already has, or previously had, another patient enrolled in the intervention group of this study
  • Your regular pharmacy is currently involved in treating another patient in this study
  • You have significant cognitive (thinking/memory) or psychiatric (mental health) difficulties that the doctor feels would make participation unsuitable (confirm with trial site)
  • Someone else, such as a carer, handles all of your medication management at home on your behalf
  • You are already taking part in another research study that might affect the results of this trial, in the doctor's opinion
  • You are an adult who is legally protected under French public health law (confirm with trial site)
  • The doctor feels you would not be able to complete the required follow-up appointments or tasks
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Roland CHAPURLAT, MD/PHD, Hospices Civils de Lyon

Phone: 04 72 11 74 82

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 June 2022
Est. completion
28 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Medication adherence to rheumatoid arthritis treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov